Disclosures. Overall Goals. Objectives. What s worth the PA forms for Patients in the Safety Net? None relevant
|
|
- Michael Cannon
- 5 years ago
- Views:
Transcription
1 Disclosures What s worth the PA forms for Patients in the Safety Net? None relevant Janet Leung, MD ZSFG Clinical Assistant Professor of the Underserved CME Feb. 25, 2017 Objectives Consider your overall goals Consider starting A1c Consider patient factors to adherence, RF for side effects New agents GLP-1 agonists SGLT-2 inhibitors DPP-4 inhibitors CME question; Pearls Overall Goals Population goal is A1c <7% = Estimated average glucose of 154 mg/dl <8% for >80 years older limited life-expectancy Why? Limit long-term complications Limit short-term complications Infection risk, wound healing Limit symptoms For diabetics, glucosuria at glucose > 200 mg/dl 1
2 Limiting Complications Lower A1c, especially early in disease: microvascular disease and macrovascular disease many years later Limit hospitalizations, symptoms A1c increases risk of hypoglycemia A1c is not protective in insulin-dependent Hypoglycemia can be fatal: arrhythmia, neuroglycopenia, cognitive impairment Challenges of Underserved Populations Lack of insurance Lack of coverage for tes ng supplies = A1c 0.5% in per Language barriers Health literacy and numeracy Lack of refrigeration Insulin stable at room temperature x 1 month once opened May need 1 month x 11 refills rather than 3 months x 3 refills Convenience if working outside home, pen insulin (vs vial) for short-acting may improve adherence Food insecurity 1/7 Americans are food insecure Higher in ethnic and racial minority households ADA Standards of Medical Care in Diabetes p Limiting Complications: Effect of Intensive Control on Complications Study Microvasc CVD Mortality UKPDS DCCT / EDIC* ACCORD ADVANCE VADT Initial Trial Kendall DM, Bergenstal RM. International Diabetes Center 2009 Long Term Follow-up * in T1DM 2
3 Limiting Complications: Other RF: BP Limiting Complications: Other RF: Lipids Tight Glucose vs Tight Blood Pressure Control in the UKPDS AHA/ACC 2013 guidelines: Age with diabetes: statins (moderate-high) >75 with diabetes: moderate statin <40 with diabetes and not getting pregnant: discuss with patient UKPDS 33 vs 38 (Type 2 diabetes) Statins for almost all diabetics (atorvastatin now generic) Drug Options Metformin ALWAYS: keep until GFR <30 (½ dose if GFR45-60) Start low (500mg daily), at bedtime if needed, titrate up to 2g per day ~80% of patients who can t tolerate immediate release bc of GI SE are fine when switched to ER A1c > 10: start insulin with metformin Brings sugars down fastest, resolve hyper symptoms (polys) Then can titrate down/try other agents ADA Standards of Medical Care in Diabetes p Leong, Br J Diabetes Vasc Disease 2007 McGuire DK, JAMA
4 2 nd Drug after Meformin Classically, sulfonylurea (glipizide, glimepride) cheap, effective but hypoglycemia and weight gain Glimepride is daily but glipizide BID with meals (hold if not eating) TZDs: patients afraid of HF exacerbation (rosiglitazone, pioglitazone) and small risk of bladder CA, fractures (pio) A1c 1-1.5%; some risks are duration dependent Acarbose: flatulence limits use Insulin: Our Over-looked Ally Almost all forms of insurance covers some form. Walmart has vials for $24.88 If your patient can take daily medications, they are capable of taking insulin (or a family member can help them inject) If vision deficit, prescribe pen (count clicks) Ethnic minorities and women more reluctant than Caucasians and men Janson SL, Diabetes Care, 2010 Psychological Insulin Resistance My family member started insulin then was blind/had amputations/ needed dialysis/died! Answers for Patients I know it s scary that your family member has those. But it s usually caused by high sugars controlling yours now will decrease your risk of these problems. Answers for Healthcare Providers It really does! Look at the DCCT and DPP data!! Even a 1 point A1c change helps! Answers for Patients You didn t fail this is common with diabetes that overtime, your body stops producing enough insulin Hurts less than FSBG especially if reusing lancet. The fatty areas to inject have way less nerves than your fingertips! You didn t fail this is common with diabetes that over time, your body stops producing enough insulin Most patients at ~15 years will be on some insulin. Warn patients about this don t use insulin as a threat to increased medication adherence early in the disease. Answers for Healthcare Providers Use highest gauge and shortest needle - Pen: 4mm (5/32 ) x 31-32g - Syringe 6mm x 30 or 31g Most patients at ~15 years will be on some insulin. Warn patients about this don t use insulin as a threat to increase medication adherence 4
5 Uninsured in Medication USD/month DPP-4 inhibitor SGLT-2 inhibitor GLP-1 agonist Lantus & Lispro/Aspart 385 & 505 Glipizide/glimepride 9-15 TZDs 12 Acarbose 28 Walmart Walgreens Rx Savings Club* NPH & Regular (VIAL) 147 & & NPH 70/30 (VIAL) Metformin 9 $4 for IR 1g BID or $5 for IR TID; $5 for 1g 1g ER ER or $15 for 1.5g ER $4 Glip: 5mg x 30 $5 Glipizide: 5mg x 30 or or 10mg x 60 10mg x 60 DPP-4 Dipeptidyl peptidase-4 inhibitor A1c <0.7% Inhibits degradation of endogenous incretins So more insulin gets secreted and less glucagon Prices from GoodRx as of 2/2017 Walmart $4/$10 formulary without insurance *Walgreens "Prescription Savings Club" after $20/year + $5-15/mo enrollment GLP-1 Glucagon-like peptide 1 receptor agonist A1c 1-1.5% on average as add-on Stimulates GLP-1 receptors In pancreas, incretin effect: more insulin, less glucagon In brain: suppresses appetite In gut: slows emptying, increases satiety SGLT-2 Sodium Glucose Co-transporter-2 inhibitor A1c 0.5-1% Blocks glucose resorption in proximal tubule of kidney by SGLT-2 5
6 Renal Handling of Glucose (GFR L/day) x (glucose conc 90 mg/dl) = g/day filtered glucose Glucose 90% S1 10% SGLT2 SGLT1 S3 The new agents: Class Summary I rarely use DPP-4i s unless patient has predominantly prandial excursions uncontrolled by an SU + risk for dehydration or falls, and refused injectables of any sort SGLT-2 vs GLP gm No Glucose/day ( kcal) NEJM 2015: EMPA-REG trial found empagliflozin (SGLT2) decreased cardiac mortality 2016: LEADER trial found liraglutide (GLP1) decreased cardiac mortality Inzucchi SE, NEJM
7 Benefits beyond A1c and Weight SGLT-1 CV benefit thought to be class-related Study in empagliflozin (FDA labeled for CV protection) Likely applies to canagliflozin, dapagliflozin Renal protection (HR 0.61, CI vs placebo) Concern for dehydration, vulvovaginal candidasis But decreased incident/worsening nephropathy No increased risk of AKI GLP-1 agonist CV benefit in liraglutide (?unclear class effect) Renal protection (HR 0.78, CI vs placebo) Buse JB, NEJM 2016 Wanner 2016, NEJM GLP-1 agonists Liraglutide: most GI side effects, daily start with 0.6 mg, to 1.2 in 1 week, then mg daily = Saxenda (weight loss drug) Exenatide: IR (Byetta) is BID, with more GI SE Exenatide ER = Bydureon: weekly Fewer SE, but subcutaneous nodules Dulaglutide (Trulicity) Albiglutide (Tanzeum) Actually Prescribing GLP-1 Agonists Victoza (3 pens/month (18mg in 3mL/pen), pen needles x 30 days) Pen is 0.6, 1.2, or 1.8 mg dose. Max out if you can Prescribe pen needles, dial in as with insulin. Prime on first use of each pen Bydureon (4 pens/kit/month) 2mg dose only Kit (reconstitute by shaking like salad dressing) Pen (rotate and tap up to 80x against hand until clear) Both need to be shaken vigorously Trulicity (4 pens/month) 0.75 mg, and 1.5 mg dose No wait, remove stand, no need to reconstitute, needle is already on Audible 2 nd click lets you know it s done Tanzeum (4 pens/month) 30mg, and 50 mg dose 30mg dose needs to mix twist and rock x 5x, rest x 15 min, rock x 5x 50mg x 30 min Yellow liquid with air bubble, click-on included needle 7
8 Ellis SL. Ther Adv Endocrinol Metab 2015 A1c for add-on GLP-1 tx Ellis SL. Ther ADv Endocrinol Metab 2015 Weight Loss for add-on GLP-1 tx NS NS -3.8% NS NS So for A1c, liraglutide ~ dulaglutide > exenatide QW (abligutide?) > exenatide BID >~ lixisenatide Weight loss: Liraglutide > dulaglutide ~ Exenatide BID ~ exenatide weekly (?abiglutide) > lixisenatide Nausea: GLP-1 agonist: Side-Effects exenatide BID (~30%)> liraglude (18-30%) and dulaglutide (16-30%) > exenatide weekly (14-26%) > lixisenatide > albiglutide (10%) Injection site reaction: exenatide weekly (~20%) > albiglutide (~12%) > exenatide BID (~9-12%) > liraglutide (<6%) and dulaglutide (<1%) Diarrhea, abdominal pain, HR 3-5 BPM Contraindications to GLP-1 Agonists History of pancreatitis History of family history of medullary thyroid cancer or MEN2A or 2B Gastroparesis (Cholelithiasis/sludging) For exenatide, if GFR <30 Sometimes used off-label in T1DM (NOT FDAapproved!) 8
9 GLP-1 Summary In my experience, much easier to start injectable GLP-1 agonists than basal insulin Patients have less preconceived notions Low risk of lows when used alone WEIGHT LOSS! Appetite suppression Even daily is tenable for patients If you had a choice: liraglutide ~ dulaglutide > exenatide (nodules, but least GI SE) > abiglutide (less effective, laborious) Always keep on the metformin! SGLT-2 inhibitors Works by wasting glucose in the urine So the higher the glucose, the higher the polyuria and glucose loss In A1c 8, decreases A1c 0.5-1% If A1c 11, decreases A1c 2.6% Start low (dehydra on risk, hypoglycemia), then Consider pre-emptive decrease in insulin dose Be certain your patients are not Type 1 diabetics Or, if lantus dose <10 units daily, risk DKA as doesn t last 24 hr Actually Prescribing SGLT-2 inhibitors Canagliflozin (Invokana): mg before breakfast Dapagliflozin (Farxiga): 10 mg daily Empagliflozin (Jardiance): mg daily Now FDA approved for CVD Contraindications to SGLT-2 inhibitor EGFR <45 for canagliflozin and empa; <60 for dapagliflozin Relative: Ketosis prone T2DM People with recurrent UTI, GU fungal infections People at risk of AKI HyperK People with osteoporosis at risk of fracturing Meininger G et al, JCEM
10 New DM Agents Summary (1/3) Food insecurity Cheap option: Tolbutamide or glipizide with meal Oral DPP-4s as a weak precursor for prandial insulin Injectable GLP-1s are great for weight loss + glucose control Oral SGLT-2s have polyuria/access to bathroom/yeast infection/need to hydrate may be limiting SE. They work better at higher A1c (as more glucosuria, as long as can keep hydrated) New DM Agents Summary (2/3) Remember, insulin always works. Consistent basal insulin -> A1c ~8-9 Walmart s Relion $25 per vial: NPH, regular, NPH/regular 70/30 Humalog/novolog ~$200+; levemir, glargine, basaglar ~$250+ FYI: Basaglar not bioidentical to lantus Higher risk of a hypoglycemia and weight gain Your formulary and patient s co-pay will likely drive your choices New DM Agents Summary (3/3) Obesity: beyond intensive lifestyle intervention and before bariatric surgery GLP-1 agonist (esp liraglutide, dulaglutide) > SGLT-2 Cardiac disease: either SGLT-2 or liraglutide (SGLT-2 for mild HF, can likely lasix) Renal disease: slight preference for GLP-1 given risk of dehydration of SGLT2i Osteoporosis: GLP-1 > SGLT-2 (canagaflozin) Higher A1c and refuse to start insulin: SGLT-2 (can decrease A1c of 11 to 8) None of these agents are approved for T1DM Question 65 year old woman with osteoporosis, obesity (BMI 35), HTN, type 2 diabetic complicated by microalbuminuria with A1c 8 on metformin 1g BID and glipizide 5 BID, presents for evaluation. She lives alone and is scared of having hypoglycemia but will only check her sugars once a day at most. What is your best option? a) Increase glipizide to 10mg BID b) Add liraglutide daily c) Stop glipizide and add canagliflozin d) Stop glipizide and add dulaglutide once a week e) Add lantus once a day 10
11 Buzz Words 65 year old woman with osteoporosis, obesity (BMI 35), HTN, type 2 diabetic complicated by microalbuminuria with A1c 8 on metformin 1g BID and glipizide 5 BID, presents for evaluation. She lives alone and is scared of having hypoglycemia but will only check her sugars once a day at most. What is your best option? Answer a) Increase glipizide to 10mg BID Unlikely to get to A1c goal of <7 b) Add liraglutide 1.8 mg daily Liraglutide has significant side effects, so start low at 0.6 mg, and increase weekly to 1.8 mg per day as tolerated. c) Stop glipizide and add canagliflozin Unlikely to get to goal, and canagliflozin has higher risk of fracture d) Stop glipizide and add dulaglutide 0.75mg weekly Will improved glucose control and help with some weight loss. Dulaglutide + metformin is unlikely to cause hypoglycemia e) Add lantus 10 units once a day Will control his sugars but likely will increase weight gain. Higher risk of lows with concurrent glipizide. Will need titration up, Pearls for Diabetes A diet history is key in DM: not just *what* they eat but when and if: Many of our patients have high carb diets: changing it to include fiber/protein can help significantly for both glucoses, satiety, and obesity Food insecure patients: hold glipizide or short-acting insulin if not eating. Consider GLP-1, SGLT-2 End of vs Beginning of month/paycheck effect If obese, GLP-1 agonists are great If A1c >10, refuses insulin, and can keep hydrated, consider SGLT-2 If hyperglycemic + sx, start insulin early. Can always decrease/add other agents later. 11
The Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationDiabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and
More information4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis
HOW TO REGULATE DIABETES MEDICATIONS By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE Diagnosis 1 NORMAL BODY The normal pancreas releases one unit of insulin every hour all day. The normal pancreas
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes 2016: Strategies for achieving optimal diabetes control
PHASE Safety Net Community Benefit Diabetes 2016: Strategies for achieving optimal diabetes control Presented by: Lisa Gilliam, MD, PhD Clinical Leader Diabetes Program Kaiser Permanente Northern California
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More information2/9/2016. The Evolving Armamentarium for Type 2 Diabetes: Incorporating New Classes in the Treatment of Our Patients. Objectives: Pharmacists
WAYNE STATE UNIVERSITY COLLEGE OF PHARMACY & HEALTH SCIENCES FEBRUARY 28, 2016 The Evolving Armamentarium for Type 2 Diabetes: Clinical Assistant Professor, Department of Pharmacy Practice Ambulatory Care
More informationTHE NEW-ISH DIABETES MEDICINES
THE NEW-ISH DIABETES MEDICINES Using GLP1s and SGLT2s FINANCIAL DISCLOSURES None Brent Jones, MD Endocrinology Madison Medical Affiliates January 31, 2019 OBJECTIVES Gain familiarity with GLP1 receptor
More informationAdvanced Practice Education Associates. Endocrine
Advanced Practice Education Associates Endocrine Overview Diabetes Thyroid Disease 162 Copyright 2016 Advanced Practice Education Associates DIABETES MELLITUS What is the BMI cut point for screening adults
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationIntensification of Diabetic Therapy. Case studies
Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,
More informationWelcome to the PHASE Learning Community! October 31, 2018
Welcome to the PHASE Learning Community! October 31, 2018 Webinar Housekeeping 1. Dial in for audio: 303-248-0285, Access Code: 5617817 2. Lines are muted. You can chat in questions or unmute your line
More informationObjectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)
How Medicine Works to Control Blood Sugar Levels Stacie Petersen, RN, CDE Objectives Define Diabetes List how medications work (ominous octet) Identify side effects of medications for diabetes What is
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix
Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationClinical Cases in Diabetes Management. Joseph Cook D.O.
Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians
More informationNew Drugs for Diabetes
NEW DRUGS FOR DIABETES Which Ones, For Which Patients? Disclosure Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu No relevant financial relationships
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationDiabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:
Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationCase 1. Modern Management of Diabetes Mellitus. Case 3. Case 2. What should be done now? What should be done now? What should be done now?
Case 1 Modern Management of Diabetes Mellitus Type 2 Non-Insulin Medication UCSF Primary Care Update San Francisco October 24, 2014 Elizabeth J. Murphy, MD, DPhil Professor of Clinical Medicine University
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationNorthern California Chapter ACP Update In Medicine I
Northern California Chapter ACP Update In Medicine I Kurt M. Hafer MD, FACP Clinical Assistant Professor Stanford University School of Medicine Division of Primary Care and Population Health November 3,
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationType 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18
Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA
More informationDiabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018
Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018 Learning Objectives Identify medication classes available for treatment of individuals with diabetes. Demonstrate understanding
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationCollaborative Practice Agreement
Collaborative Practice Agreement [community pharmacy name] [address] [phone number] [physician practice] [address] [phone number] Effective: [date] Expiration: [date] 1 Table of Contents 1.0 Introduction...4
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationDiabetes Management: A diagnostic perspective
Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact DIABETES
More informationCURRENT ISSUES IN DIABETES MANAGEMENT
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2011 BMI
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationANGELA GINN-MEADOW RD LDN CDE
DIABETES DRUGS & TRENDS MADE SIMPLE PHARMD TO RD ANGELA GINN-MEADOW RD LDN CDE OBJECTIVES At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationDiabetes Risk Assessment and Treatment
Diabetes Risk Assessment and Treatment Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Division of Endocrinology, Diabetes, & Metabolism Johns Hopkins University Baltimore, Maryland, USA
More information